Search

Your search keyword '"Vos, Filip De"' showing total 22 results
Start Over Author "Vos, Filip De"
22 results on '"Vos, Filip De"'

2. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Author

Lim, Michael, Weller, Michael, Idbaih, Ahmed, Steinbach, Joachim Peter, Finocchiaro, Gaetano, Raval, Raju R, Ansstas, George, Bähring, Joachim, Taylor, Jennie W, Honnorat, Jerome, Petrecca, Kevin, Vos, Filip de, Wick, Antje, Sumrall, Ashley, Sahebjam, Solmaz, Mellinghoff, Ingo K., Kinoshita, Masashi, Roberts, Mustimbo, Slepetis, Ruta, Warad, Deepti, Leung, David, Lee, Michelle, Reardon, David A., Omuro, Antonio, Lim, Michael, Weller, Michael, Idbaih, Ahmed, Steinbach, Joachim Peter, Finocchiaro, Gaetano, Raval, Raju R, Ansstas, George, Bähring, Joachim, Taylor, Jennie W, Honnorat, Jerome, Petrecca, Kevin, Vos, Filip de, Wick, Antje, Sumrall, Ashley, Sahebjam, Solmaz, Mellinghoff, Ingo K., Kinoshita, Masashi, Roberts, Mustimbo, Slepetis, Ruta, Warad, Deepti, Leung, David, Lee, Michelle, Reardon, David A., and Omuro, Antonio

Abstract

Background: Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ). The purpose of the phase III randomized CheckMate 548 study was to evaluate RT + TMZ combined with the immune checkpoint inhibitor nivolumab (NIVO) or placebo (PBO) in patients with newly diagnosed glioblastoma with methylated MGMT promoter (NCT02667587). Methods: Patients (N = 716) were randomized 1:1 to NIVO [(240 mg every 2 weeks × 8, then 480 mg every 4 weeks) + RT (60 Gy over 6 weeks) + TMZ (75 mg/m2 once daily during RT, then 150-200 mg/m2 once daily on days 1-5 of every 28-day cycle × 6)] or PBO + RT + TMZ following the same regimen. The primary endpoints were progression-free survival (PFS) and overall survival (OS) in patients without baseline corticosteroids and in all randomized patients. Results: As of December 22, 2020, median (m)PFS (blinded independent central review) was 10.6 months (95% CI, 8.9-11.8) with NIVO + RT + TMZ vs 10.3 months (95% CI, 9.7-12.5) with PBO + RT + TMZ (HR, 1.1; 95% CI, 0.9-1.3) and mOS was 28.9 months (95% CI, 24.4-31.6) vs 32.1 months (95% CI, 29.4-33.8), respectively (HR, 1.1; 95% CI, 0.9-1.3). In patients without baseline corticosteroids, mOS was 31.3 months (95% CI, 28.6-34.8) with NIVO + RT + TMZ vs 33.0 months (95% CI, 31.0-35.1) with PBO + RT + TMZ (HR, 1.1; 95% CI, 0.9-1.4). Grade 3/4 treatment-related adverse event rates were 52.4% vs 33.6%, respectively. Conclusions: NIVO added to RT + TMZ did not improve survival in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter. No new safety signals were observed.

Published
2022

5. Additional file 1: of Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts

Author

Melsens, Elodie, Vlieghere, Elly De, Descamps, Benedicte, Vanhove, Christian, Kersemans, Ken, Vos, Filip De, Goethals, Ingeborg, Brans, Boudewijn, Wever, Olivier De, Ceelen, Wim, and Pattyn, Piet

Abstract

Figure S1. In vitro effect of nimorazole monotherapy. Ctrl = control; Nimo = nimorazole; Norm = normoxia; Hypox = hypoxia. Y-axis shows absorbance, analyzed 72 h after treatment. No significant difference was observed between cells treated with PBS (control) or treated with nimorazole, under hypoxic or normoxic conditions (t-test). (DOCX 20 kb)

Published
2018
Full Text
View/download PDF

6. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Author

Bent, Martin Van Den, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, Vos, Filip De, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, and Nuyens, Sarah

Published
2020
Full Text
View/download PDF

7. The Signature of the Serotonin System in the Chronic Corticosterone Depression Model: A Study with [18F] MPPF, [18F] Altanserin and [11C] DASB

Author

Pauwelyn, Glenn, primary, Laeken, Nick Van, additional, Verhoeven, Jeroen, additional, Vos, Filip De, additional, Peremans, Kathelijne, additional, Dockx, Robrecht, additional, Baeken, Chris, additional, Descamps, Benedicte, additional, Vanhove, Christian, additional, Kersemans, Ken, additional, and Goethalse, Ingeborg, additional

Published
2018
Full Text
View/download PDF

8. Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients

Author

Huysse, Wouter, primary, Lecouvet, Frédéric, additional, Castellucci, Paolo, additional, Ost, Piet, additional, Lambrecht, Valerie, additional, Artigas, Carlos, additional, Denis, Marie-Laurence, additional, Man, Kathia De, additional, Delrue, Louke, additional, Jans, Lennart, additional, Bruycker, Aurélie De, additional, Vos, Filip De, additional, Meerleer, Gert De, additional, Decaestecker, Karel, additional, Fonteyne, Valerie, additional, and Lambert, Bieke, additional

Published
2017
Full Text
View/download PDF

9. Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model

Author

Meille, Christophe, primary, Guerreiro, Nelson, additional, Jullion, Astrid, additional, Bauer, Sebastian, additional, Chatterjee, Manik, additional, Vos, Filip de, additional, Lin, Chia-Chi, additional, Rodríguez, Cristina Suárez, additional, Tai, David, additional, Cassier, Philippe, additional, Yamamoto, Noboru, additional, Weger, Vincent A. de, additional, Klopfenstein, Matthieu, additional, Mariconti, Luisa, additional, Kuriakose, Emil T., additional, and Hyman, David M., additional

Published
2017
Full Text
View/download PDF

10. Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts withTP53wt advanced tumors

Author

Hyman, David M., primary, Chatterjee, Manik, additional, Vos, Filip de, additional, Lin, Chia-Chi, additional, Suárez, Cristina, additional, Tai, David, additional, Cassier, Philippe, additional, Yamamoto, Noboru, additional, Weger, Vincent A. de, additional, Jeay, Sébastien, additional, Meille, Christophe, additional, Halilovic, Ensar, additional, Mariconti, Luisa, additional, Klopfenstein, Matthieu, additional, Guerreiro, Nelson, additional, Radhakrishnan, Rajkumar, additional, Kuriakose, Emil T., additional, and Bauer, Sebastian, additional

Published
2017
Full Text
View/download PDF

11. Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias

Author

Stein, Eytan, primary, Chromik, Joerg, additional, DeAngelo, Daniel J., additional, Chatterjee, Manik, additional, Noppeney, Richard, additional, Vos, Filip de, additional, Minami, Hironobu, additional, Jeay, Sébastien, additional, Meille, Christophe, additional, Halilovic, Ensar, additional, Mariconti, Luisa, additional, Klopfenstein, Matthieu, additional, Guerreiro, Nelson, additional, Radhakrishnan, Rajkumar, additional, Kuriakose, Emil T., additional, and Carpio, Cecilia, additional

Published
2017
Full Text
View/download PDF

13. Sizing Nanomatter in Biological Fluids by Fluorescence Single Particle Tracking

Author

Braeckmans, Kevin, primary, Buyens, Kevin, additional, Bouquet, Wim, additional, Vervaet, Chris, additional, Joye, Philippe, additional, Vos, Filip De, additional, Plawinski, Laurent, additional, Doeuvre, Loïc, additional, Angles-Cano, Eduardo, additional, Sanders, Niek N., additional, Demeester, Jo, additional, and Smedt, Stefaan C. De, additional

Published
2010
Full Text
View/download PDF

16. In VitroScreening for Synergism of High-Linear Energy Transfer213Bi-Radiotherapy with Other Therapeutic Agents for the Treatment of B-Cell Chronic Lymphocytic Leukemia

Author

Vandenbulcke, Katia, primary, Thierens, Hubert, additional, Vos, Filip De, additional, Philippé, Jan, additional, Offner, Fritz, additional, Janssens, Ann, additional, Apostolidis, Christos, additional, Morgenstern, Alfred, additional, Bacher, Klaus, additional, de Gelder, Virginie, additional, Dierckx, Rudi A., additional, and Slegers, Guido, additional

Published
2006
Full Text
View/download PDF

17. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.

Author

Decaestecker, Karel, De Meerleer, Gert, Lambert, Bieke, Delrue, Louke, Fonteyne, Valérie, Claeys, Tom, Vos, Filip De, Huysse, Wouter, Hautekiet, Arne, Maes, Gaethan, and Ost, Piet

Subjects
STEREOTACTIC radiotherapy, PROSTATE cancer, CANCER relapse, METASTASIS, POSITRON emission tomography, COMPUTED tomography, ANDROGENS, PROGRESSION-free survival
Abstract

Purpose To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT). Methods Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) diagnosed on positron emission tomography - computed tomography, following biochemical recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADTFS) defined as the time interval between the first day of SBRT and the initiation of ADT was the primary endpoint. ADT was initiated if more than 3 metastases were detected during follow-up even when patients were still asymptomatic. Secondary endpoints were local control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common Terminology Criteria for Adverse Events. Results With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 metastatic lesions with a local control rate of 100%. The primary involved metastatic sites were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% CI: 13-25 mo) with 75% of recurring patients having ⩽3 metastases. A 2nd and 3rd course of SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 months (20-30 mo). On univariate analysis, only a short PSA doubling time was a significant predictor for both PFS (HR: 0.90, 95%CI: 0.82 - 0.99) and ADT-FS (HR: 0.83; 95%CI: 0.71 - 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 7 and grade II in 3 patients. Conclusion Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

20. 99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression

Author

Caveliers, Vicky, Cortez-Retamozo, Virna, Lahoutte, Tony, Tchouate Gainkam, Lea Olive, Hernot, Sophie, Packeu, Ann, Vos, Filip De, Vanhove, Chris, Muyldermans, Serge, Baetselier, Patrick De, and Revets, Hilde

Abstract

Introduction: The development of specific radiolabeled probes towards molecular markers in vivo has gained interest as targeted imaging allows for a more accurate detection of diseases. We investigate the feasibility of targeted imaging of cancer antigens using the variable domain of single chain camelid antibodies (Nanobodies®) labeled with 99mTechnetium. Nanobodies against carcinoembryonic antigen (CEA) were used as a model. Methods: His6-CEA1 Nanobodies were generated and labeled with 99mTc at their His-tag using Tc(I)-tricarbonyl (Isolink, Mallinckrodt, B.V., Petten, The Netherlands). The normal biodistribution was assessed in healthy athymic mice by ex vivo analysis at 1 and 3 h. In vivo targeting was evaluated in the same mouse model bearing the CEA-positive LS174T tumour or a CEA-negative A431 (human skin carcinoma) control tumour. Pinhole SPECT imaging was performed at 3 hours after intravenous injection of 90 MBq 99mTc-His6-CEA1 using a dual-headed gamma camera equipped with pinhole collimators. Results: Radiolabeling efficiency was 95%. General biodistribution showed intense renal uptake and marked liver accumulation. Using pinhole-SPECT, the average uptake of 99mTc- His6-CEA1 in LS174T (CEA positive) was significantly higher compared to the A431 (CEA negative) control tumour: respectively 3.2 ± 0.6 %IA/cm3 and 1.1 ± 0.2 %IA/cm3 (p < 0.05). Conclusion: This study presents effective labeling of Nanobodies with 99mTc using Tc(I)-carbonyl chemistry and shows their potential as a new type of specific probes for imaging antigen expression.

Published
2008

21. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Author

van den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, Vos, Filip de, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, and Nuyens, Sarah

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results